Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Biol Ther. 2013 Apr;13(4):615-22. doi: 10.1517/14712598.2013.778239. Epub 2013 Mar 4.

Canakinumab in pediatric rheumatic diseases.

Author information

1
University medical Center Utrecht, Department Pediatric Rheumatology, Utrecht, Netherlands. N.wulffraat@umcutrecht.nl

Abstract

INTRODUCTION:

Hitherto, some of the most severe forms of arthritis with onset in the neonatal period and early childhood have been resistant to conventional and anti-tumour necrosis factor agents. Recent results from drug trials of novel monoclonal antibodies will significantly alter the treatment of two of these diseases. This review is for canakinumab, a new monoclonal antibody to interleukin 1β that has been shown to be specifically efficacious in two groups of arthritis with systemic features.

AREAS COVERED:

The clinical features and treatment to-date in the autoinflammatory disease, cryopyrin associated periodic fever syndrome and systemic juvenile idiopathic arthritis are briefly reviewed. An overview of current IL-1 inhibitors is provided. Clinical trials of Canakinumab in the treatment of these two diseases are evaluated.

EXPERT OPINION:

The last decade has seen a major advance in treatment leading to remission while on therapy for many children with CAPS and sJIA. The outcomes of the anti-IL-1β and the anti-IL-6 trials for sJIA are quite similar and do not enable preferential use of either biological in a given patient.

PMID:
23451862
DOI:
10.1517/14712598.2013.778239
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center